Analysts Issue Forecasts for PBLS Q3 Earnings

Parabilis Medicines, Inc. (NASDAQ:PBLS) – Research analysts at HC Wainwright issued their Q3 2026 earnings per share estimates for Parabilis Medicines in a research report issued on Thursday, October 22nd. HC Wainwright analyst R. Burns anticipates that the company will earn ($0.35) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Parabilis Medicines’ current full-year earnings is ($2.60) per share. HC Wainwright also issued estimates for Parabilis Medicines’ Q4 2026 earnings at ($0.36) EPS, FY2026 earnings at ($2.10) EPS, Q1 2027 earnings at ($0.37) EPS, Q2 2027 earnings at ($0.38) EPS, Q3 2027 earnings at ($0.39) EPS, Q4 2027 earnings at ($0.40) EPS and FY2027 earnings at ($1.55) EPS.

Several other analysts have also recently weighed in on the stock. Evercore began coverage on shares of Parabilis Medicines in a report on Monday, July 6th. They issued an “outperform” rating on the stock. Bank of America assumed coverage on Parabilis Medicines in a report on Monday, July 6th. They issued a “buy” rating and a $45.00 target price for the company. Zacks Research upgraded shares of Parabilis Medicines to a “hold” rating in a research note on Tuesday, July 7th. Leerink Partners started coverage on Parabilis Medicines in a report on Monday, July 6th. They set an “outperform” rating and a $40.00 price target on the stock. Finally, Guggenheim initiated coverage on Parabilis Medicines in a research report on Monday, July 6th. They issued a “buy” rating and a $40.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Parabilis Medicines presently has an average rating of “Moderate Buy” and a consensus target price of $41.25.

Parabilis Medicines Stock Up 5.9%

PBLS opened at $26.51 on Monday. The business’s fifty day moving average is $33.66. Parabilis Medicines has a 12 month low of $22.66 and a 12 month high of $42.49.

Parabilis Medicines (NASDAQ:PBLS) last released its earnings results on Thursday, August 13th. The company reported ($2.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($2.16). The company had revenue of $0.15 million during the quarter.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Alphabet Inc. purchased a new stake in shares of Parabilis Medicines in the second quarter valued at about $134,647,000. General Catalyst Group Management LLC purchased a new position in Parabilis Medicines during the second quarter worth $43,818,000. WINTON GROUP Ltd acquired a new position in shares of Parabilis Medicines in the second quarter worth $955,000. Squarepoint Ops LLC acquired a new position in shares of Parabilis Medicines in the second quarter worth $1,327,000. Finally, ICONIQ Capital LLC acquired a new position in shares of Parabilis Medicines in the second quarter worth $9,580,000.

About Parabilis Medicines

Parabilis Medicines Inc is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc is based in CAMBRIDGE, Mass.